3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
20
Carcinoma, Non-Small-Cell Lung
20
Carcinoma, Hepatocellular
15
Brain Neoplasms
12
Breast Neoplasms
10
Pancreatic Neoplasms
9
Neoplasm Metastasis
9
Lung Neoplasms
5
Neoplasms
4
Recurrence
3
Colorectal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neuroma, Acoustic
2
NSCLC
2
Liver Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Esophageal Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
1
Stage IA - IB Non Small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Spine Metastasis
1
Spinal Neoplasms
1
Spinal Bone Metastases
1
Solid Tumor
1
Sarcoma
1
Rare Diseases
1
Radiotherapy
1
Interventions
CTLA-4 Antigen
2
envafolimab
1
Radiosurgery
1
Radiation
1
Paclitaxel
1
Doxorubicin
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Radiosurgery
×
Clear all
NCT05915481
2023-06-23
SCARCE
Peking University Third Hospital
Phase 1/2
Unknown
60 enrolled